Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Medically reviewed by Laura Young Endometriosis occurs when tissue that lines the uterus (womb) grows elsewhere, usually on ...

Scientists discover that cancer treatment DCA may help endometriosis patients by targeting the disease's abnormal cellular metabolism ...

Profiling cells from ovarian endometriosis revealed signaling interactions that may sustain legion growth, highlighting ...

A report reveals endometriosis leads to lower wages and job loss for women, highlighting workplace stigma and causing uproar ...

Endometriosis can be a brake on women's careers Endometriosis is a chronic, inflammatory, hormone-dependent gynecological disease that affects around 10% of women of childbearing age. The main ...

Reproductive steroids are powerful hormones that play a key role in the growth and development of our bodies, especially during puberty.

Severe pelvic pain during menstrual periods is the main symptom of endometriosis. Other symptoms include excessive bleeding ...

The Albanese government has announced half a billion in funding for women's health reforms in Australia, so what's the real ...

Women's Health in the South East (WHISE) applauds the Australian Government's $573.3 million investment in women's health, which will improve access ...

There is a 10 per cent rise in endometriosis cases among women, with one in 10 women getting diagnosed with the condition per ...

The Albanese government has unveiled a significant $573.3 million investment that’s aiming for better access, lower cost, and more choice in women’s healthcare. From cheaper contraceptives to more ...